SBC003
Asset
Induces neuroglobin expression via p-body modulation to protect neurons through an endogenous, mutation-agnostic pathway.
- Stage
- Preclinical
- Modality
- Small molecule
- Target
- Not known
- 6
- Indications
- 0
- Trials
- 1
- Developer
Indications
6ALS
Preclinical, sunregen.com, Oct 10, 2026
Alzheimer's disease
Preclinical, sunregen.com, Oct 10, 2026
Dry age-related macular degeneration
Preclinical, sunregen.com, Oct 10, 2026
3 more
In the full profile
- Owner and partners1
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.